Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Person › Details

Edwin Moses (Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX))

Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)


Organisations Organisation Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
  Group Ablynx (Group)
  Former/major organisation Oxford Asymmetry International plc
  Today Aptuit Ltd.
  Group Evotec (Group)
Product Product Nanobodies®

Ablynx N.V.. (1/29/16). "Press Release: Ablynx to Receive €8 Million Milestone as Boehringer Ingelheim Starts First Patient Study with a Bi-specific Nanobody in Oncology". Ghent.

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the study is to evaluate the safety profile and dosing schedule for this Nanobody.

The anti-VEGF/Ang2 Nanobody was discovered and developed as part of the Strategic Alliance between both parties, signed in September 2007. This Nanobody blocks both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), important proteins which are involved in the formation of new blood vessels from pre-existing vessels (angiogenesis), a vital mechanism in the growth of tumours.

Dr Edwin Moses, CEO of Ablynx, commented: “We are very pleased that the first bi-specific Nanobody, as part of our collaboration with Boehringer Ingelheim, has entered clinical development. The formatting flexibility and ability to link different Nanobodies together to bind to different proteins and/or epitopes is a key feature of our technology and is of particular interest in cancer drug development. We are looking forward to seeing more of these innovative product candidates enter the clinic in the future.”

The results from the pre-clinical study have been presented by Boehringer Ingelheim at the 8th Euro Global Summit on Cancer Therapy and demonstrated that this bi-specific Nanobody potently inhibits VEGF and Ang2 signalling in multiple in vivo cancer models and strongly impairs proliferation and survival of human endothelial cells. In addition, the bi-specific Nanobody showed superior efficacy as compared to inhibition of the individual pathways by the reference monoclonal antibody drugs. The Nanobody was also found to be well tolerated in cynomolgus

About Strategic Alliance between Boehringer Ingelheim and Ablynx

In September 2007, Ablynx and Boehringer Ingelheim entered into a Strategic Alliance on the discovery, development and commercialisation of Nanobody therapeutics across a range of diseases, including oncology, immunology, respiratory and vascular diseases. The agreement allows for potential milestone payments of up to €125 million plus royalties to Ablynx for each Nanobody which reaches the market. Boehringer Ingelheim is exclusively responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration. Ablynx retains certain co-promotion rights in Europe. To date, Ablynx has earned >€75 million in cash from this Strategic Alliance and in addition to the anti-VEGF/Ang2 Nanobody there are a number of other programmes advancing through pre-clinical development, all fully funded by Boehringer Ingelheim.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immunooncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on

For more information, please contact:


Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03

Ablynx media relations:

Instinctif Partners
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors’ current expectations and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results
or events to differ materially from those expressed or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events
described herein. A multitude of factors including, but not limited to, changes in demand, competition and
technology, can cause actual events, performance or results to differ significantly from any anticipated development.
Forward looking statements contained in this press release regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims
any obligation or undertaking to release any update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor
any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual
occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements,
which speak only as of the date of this press release.

Record changed: 2019-06-09


Picture [iito] Männer Ballett 650x80px

More documents for Edwin Moses

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top